Document Detail

Low dosage treatment with propiono-hydroxamic acid in paraplegic patients.
MedLine Citation:
PMID:  2653839     Owner:  NLM     Status:  MEDLINE    
Severe urinary tract infections due to urease-producing bacteria are frequently associated with neurourologic pathologies and complicated by infected nephrolithiasis. Hydroxamic acids, acting as urease inhibitors, can effectively reduce lithiasic risk, normalizing the urinary environment, as well as enhancing the action of antibiotic treatments. A low dosage propiono-hydroxamic acid (PHA) treatment, 60 mg twice a day for 7 days and then 60 mg/day, was used in 15 patients affected with neurourologic pathologies for 3 months. Nine patients were stone-free and 6 stone-bearers. Urinary pH and ammonium decreased in both groups. Halving the PHA dose did not cause any variation in urinary pH or ammonium trends. In the stone-bearing group an increase in these parameters was correlated with urinary infection recurrences. Complete sterilization was achieved in 11 of 14 patients who completed the trial. In the stone-free group no patient had an infectious recurrence after the first month. Two patients in the stone-bearing group had repeated recurrences. One patient dropped out after 45 days due to a decrease in platelets. The efficacy of such low dose treatment makes even long-term or repeated therapies possible, as is often needed by neurourologic patients.
A Tizzani; R Carone; G Casetta; P Piana; D Vercelli
Related Documents :
12837409 - Extracorporeal shock wave lithotripsy in anomalous kidneys: 11-year experience with two...
664139 - Partial nephrectomy in surgical treatment of calculous disease.
9830579 - Complex cystic duct is associated with cholelithiasis.
1398239 - Postoperative bile leakage: endoscopic management.
18687199 - Current place of vasopressin analogues in the treatment of septic shock.
17377509 - Hyperoxaluric nephrolithiasis is a complication of roux-en-y gastric bypass surgery.
19371389 - Influence of varnish application on a tissue conditioner: analysis of biofilm adhesion.
21490819 - The optimal volume of 0.2% ropivacaine required for an ultrasound-guided stellate gangl...
8661629 - Disadvantages of muscle-sparing thoracotomy in patients with lung cancer.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  European urology     Volume:  16     ISSN:  0302-2838     ISO Abbreviation:  Eur. Urol.     Publication Date:  1989  
Date Detail:
Created Date:  1989-06-22     Completed Date:  1989-06-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7512719     Medline TA:  Eur Urol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  36-40     Citation Subset:  IM    
Institute of Nephrourology, University of Turin, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Ammonia / analysis
Anti-Bacterial Agents / administration & dosage,  therapeutic use
Clinical Trials as Topic
Drug Therapy, Combination
Hydrogen-Ion Concentration
Hydroxamic Acids / administration & dosage*,  therapeutic use
Paraplegia / complications*
Urinary Bladder Diseases / etiology
Urinary Calculi / prevention & control
Urinary Tract Infections / prevention & control*
Urine / analysis
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Hydroxamic Acids; 2580-63-4/propionohydroxamic acid; 7664-41-7/Ammonia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Autogenous skin and fascia grafts as topical hemostatic agents in splenic injuries.
Next Document:  Prostatic epithelial polyp of the prostatic urethra.